Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

BioNTech SE (BNTX)

169.74   0.27 (0.16%) 12-02 16:00
Open: 167.11 Pre. Close: 169.47
High: 169.89 Low: 166.748
Volume: 714,778 Market Cap: 41,193(M)

Technical analysis

as of: 2022-12-02 4:21:22 PM
Overall:       
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 198.99     One year: 232.42
Support: Support1: 147.58    Support2: 133.5
Resistance: Resistance1: 170.36    Resistance2: 198.99
Pivot: 162.38
Moving Average: MA(5): 166.26     MA(20): 161.4
MA(100): 149.56     MA(250): 162.41
MACD: MACD(12,26): 5.8     Signal(9): 5.6
Stochastic oscillator: %K(14,3): 97.3     %D(3): 91.5
RSI: RSI(14): 66.8
52-week: High: 302.33  Low: 117.08
Average Vol(K): 3-Month: 897 (K)  10-Days: 805 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ BNTX ] has closed below upper band by 12.3%. Bollinger Bands are 23.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 169.99 - 170.49 170.49 - 171.06
Low: 165.21 - 165.83 165.83 - 166.52
Close: 168.64 - 169.58 169.58 - 170.63

Company Description

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

Headline News

Thu, 01 Dec 2022
Can BioNTech SE - ADR (BNTX) Stock Rise to the Top of Healthcare Sector Thursday? - InvestorsObserver

Thu, 01 Dec 2022
BioNTech (BNTX) Inks Research Deal With Ryvu Therapeutics - Nasdaq

Mon, 21 Nov 2022
JPMorgan Chase & Co. Analysts Give BioNTech (NASDAQ:BNTX) a $148.00 Price Target - MarketBeat

Tue, 15 Nov 2022
Here are the Reasons to Invest in BioNTech SE (BNTX) - Yahoo Finance

Thu, 10 Nov 2022
What is Wall Street's Target Price for BioNTech SE - ADR (BNTX) Stock Thursday? - InvestorsObserver

Wed, 09 Nov 2022
BioNTech (NASDAQ:BNTX) Seems To Use Debt Rather Sparingly - Simply Wall St

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 243 (M)
Shares Float 90 (M)
% Held by Insiders 62.9 (%)
% Held by Institutions 16.9 (%)
Shares Short 2,140 (K)
Shares Short P.Month 3,250 (K)

Stock Financials

EPS 41.66
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 76.44
Profit Margin (%) 55.5
Operating Margin (%) 68
Return on Assets (ttm) 42.8
Return on Equity (ttm) 76.2
Qtrly Rev. Growth -43.1
Gross Profit (p.s.) 66.21
Sales Per Share 76.47
EBITDA (p.s.) 52.45
Qtrly Earnings Growth -43.5
Operating Cash Flow 12,550 (M)
Levered Free Cash Flow 10,200 (M)

Stock Valuations

PE Ratio 4.07
PEG Ratio -0.2
Price to Book value 2.22
Price to Sales 2.21
Price to Cash Flow 3.28

Stock Dividends

Dividend 2.1
Forward Dividend 0
Dividend Yield 1.2%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.